Literature DB >> 9657098

Expression of vascular endothelial growth factor in human hepatocellular carcinoma.

R Yamaguchi1, H Yano, A Iemura, S Ogasawara, M Haramaki, M Kojiro.   

Abstract

Vascular endothelial growth factor (VEGF) is thought to take an important role in tumor angiogenesis. The present study examined VEGF expression immunohistochemically in hepatocellular carcinomas (HCCs) in various histological grades and sizes. In HCCs that were composed of cancerous tissues of single histological grade, VEGF expression was the highest in well-differentiated HCCs, followed by moderately differentiated HCCs, and then poorly differentiated HCCs. VEGF positivity gradually decreased with the increase in tumor size. In the nodules larger than 3.0 cm, 36.8% were VEGF-negative. In HCCs consisting of cancerous tissues of two different histological grades, the expression was less intensive in the higher-grade HCC component. VEGF was not expressed in sarcomatous areas, while VEGF was expressed in the surrounding HCC tissues. The expression was also remarkable in the noncancerous tissues in which inflammatory cell infiltration was apparent. VEGF expression was also examined in six HCC cell lines. In reverse-transcription polymerase chain reaction (RT-PCR) analysis, expressions of the two secretion types (VEGF121 and VEGF165) were the highest. Thus, VEGF protein in culture supernatant was measured by using enzyme-linked immunosorbent assay (ELISA) with or without inflammatory cytokines, i.e., interleukin (IL)-1beta, interferon (IFN)-alpha, IFN-gamma, and tumor necrosis factor (TNF)-alpha; and growth factors, i.e., epidermal growth factor (EGF), platelet-derived growth factor (PDGF)-BB, basic fibroblast growth factor (bFGF), and transforming growth factor (TGF)-alpha. As a result, secretion of VEGF from the cell lines was upregulated at various degrees. Based on these findings, VEGF expression in HCC tissues was thought to be related to the histological grade. The findings also indicate that various cytokines and growth factors could cooperatively act to enhance VEGF expressions in HCC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657098     DOI: 10.1002/hep.510280111

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  96 in total

1.  MR imaging in hepatocellular carcinoma: correlations between MRI features and molecular marker VEGF.

Authors:  Zhaoqin Huang; Xiangjiao Meng; Jianjun Xiu; Xiuqin Xu; Lei Bi; Jie Zhang; Xue Han; Qingwei Liu
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  Study on the changes in microvessel density in hepatocellular carcinoma following transcatheter arterial chemoembolization.

Authors:  J Yi; X Liao; Z Yang; X Li
Journal:  J Tongji Med Univ       Date:  2001

3.  From liver cirrhosis to HCC.

Authors:  Luigi Bolondi; Laura Gramantieri
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

4.  Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.

Authors:  Wan-Nan Chen; Jin-Yan Chen; Bo-Yan Jiao; Wan-Song Lin; Yun-Li Wu; Ling-Ling Liu; Xu Lin
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

5.  Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues.

Authors:  Geertu Deli; Can-Hao Jin; Rong Mu; Song Yang; Yue Liang; De Chen; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

6.  Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition.

Authors:  Satoshi Mamori; Tadashi Asakura; Kiyoshi Ohkawa; Hisao Tajiri
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

Review 7.  Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.

Authors:  D Germano; V Tinessa; E Barletta; L Cannella; B Daniele
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

Review 8.  Cancer-associated fibroblasts in hepatocellular carcinoma.

Authors:  Norio Kubo; Kenichiro Araki; Hiroyuki Kuwano; Ken Shirabe
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

9.  Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.

Authors:  Xin Li; Gan-Sheng Feng; Chuan-Sheng Zheng; Chen-Kai Zhuo; Xi Liu
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

10.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Authors:  Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.